Alt Pep is a biomedical startup focused on transforming the diagnosis and treatment of amyloid diseases, including Alzheimer’s and Parkinson’s. Their innovative platform utilizes custom-designed synthetic peptides to selectively target and neutralize toxic oligomers associated with these diseases, enabling early detection and intervention. With a strong emphasis on scientific research and development, Alt Pep aims to make significant breakthroughs that could impact over a billion people globally, positioning itself as a leader in the biotech space.
Arbor Biotechnologies is pioneering next-generation gene editing to revolutionize the treatment of genetic diseases. The company focuses on discovering and developing genomic medicines that address the root causes of these diseases, utilizing a diverse toolbox of novel gene editors. With a commitment to curing all patients suffering from genetic conditions, Arbor is positioned at the forefront of the biotech industry, leveraging advanced technologies to rewrite the human genome and provide functional cures.
Arc Boats is revolutionizing the marine industry with 100% electric recreational boats, starting with the Arc One and the Arc Sport. Founded in 2021 in Los Angeles, CA, the company combines aerospace engineering with traditional craftsmanship to create high-performance boats that are clean, quiet, and require minimal maintenance. With a strong focus on sustainability and innovation, Arc Boats aims to set new industry standards and expand the market for electric boating, backed by significant funding and a growing team of experts.
Autobahn Therapeutics is a biotechnology company focused on developing next-generation regenerative medicines for CNS disorders. The company leverages a brain-targeting chemistry platform to create orally administered small molecule prodrugs, aiming to restore the brain to a healthier state and address the progressive nature of CNS conditions. Their lead product, ABX-002, is being developed for major depressive disorder and bipolar depression, with a strong emphasis on biomarker-driven development and validated human biology to de-risk their pipeline. With a world-class team and significant backing from investors, Autobahn is positioned to make a meaningful impact in the CNS therapeutic landscape.
Basecamp Research is dedicated to tackling the toughest challenges in life sciences by pushing the boundaries of known biology. With the world’s largest biological database, we give AI a complete understanding of the true breadth and complexity of biology. This allows us to design complete biological systems with controllability, novelty and performance that far exceeds the previous state of the art. Today, our partners include trail-blazing labs and several of the top 10 biopharma companies. Our unique knowledge graph is driving breakthrough performance – going far beyond previous speed and complexity limits, and we are proud to partner with biodiversity partners across the globe, building a foundational database tailored to AI.
Big Hat Biosciences is a Series B biotech company based outside San Francisco that leverages machine learning and synthetic biology to design safer and more effective antibody therapies. Their Milliner platform integrates a high-speed wet lab with advanced machine learning technologies, enabling the rapid synthesis, purification, and characterization of hundreds of recombinant antibodies weekly. With a pipeline of wholly-owned and partnered therapeutic programs, Big Hat has raised over $100 million from top investors and is recognized for its innovative approach to tackling complex diseases through next-generation antibody therapies.